← Leaderboards
Anna Berkenblit
Beth Israel Deaconess Medical Center
$63,990
Attributed
$63,990
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$63,990 · 3
By mechanism
M01$63,990 · 3
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Michael B Atkins$4,622,469
- Susan L Greenspan$27,746,173
- Steven C. Schachter$10,007,385
- K Lea Sewell$387,832
- Mary Albrecht$387,832
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsClinical ResearchClinical Trial Phase ICombination ChemotherapyDosageDrug Screening /EvaluationHuman SubjectHuman Therapy EvaluationNeoplasm /CancerNeoplasm /Cancer ChemotherapyPaclitaxelPatient Oriented Research
Grant awards (4)
STA-4783 FOR PATIENTS WITH SOLID TUMORS$10,011
M01 · FY2005 · RR
OPEN LABEL EXPLORATORY STUDY OF CF101 AND CHEMOTHERAPY IN ADVANCED SOLID TUMORS$9,102
M01 · FY2005 · RR
A PHASE I STUDY OF PT523 IN PATIENTS WITH SOLID TUMORS$5,006
M01 · FY2005 · RR
STA-4783 for Patients with Solid Tumors$39,871
M01 · FY2004 · RR